Default company panoramic image
Logo

Anergis

Anergis is a clinical stage Swiss biotech developing breakthrough allergy vaccines for ultra-fast and safe desensitisation in only 2 months

  • Stage Product In Development
  • Industry Biotechnology
  • Location Chemin des Croisettes, Epalinges, VD, Switzerland
  • Currency CHF
  • Founded June 2001
  • Employees 10
  • Website anergis.ch

Company Summary

Anergis SA discovers and develops breakthrough allergy vaccines targeting the most frequent allergies, based on its proprietary Continuous Overlapping Peptides technology. Anergis lead-product is in Phase IIb clinical development with efficacy and safety results expected by August-Sept 2013. Anergis has two more allergy vaccines in preclinical development against house dust mites allergy and ragweed allergy.

Team

  • Default avatar
    Vincent Charlon
    CEO

    CEO Anergis since 2009
    CEO LS Pharma 2007-2008
    CEO Hesperion (CRO) 1998-2007
    Clinical Director Roche USA 1994-1998
    Clinical Scientist Roche Basel CH 1990-1993
    Clinical Scientist, Eliac Phase I Unit, France

    At Hesperion, completed two acquisitions/integrations and the trade sale of Hesperion. Developed Hesperion from 1 to 200 employees in 8 countries.

  • Default avatar
    Christophe Reymond
    CSO

    CSO Anergis since 2005
    2005-2008 CSO and COO of Anergis
    CSO and co-founder of RMF Dictagene 1991-2005
    Professor of Cellular Biology, University of Medecine, Lausanne

    Specialized in immunology, allergy, long peptides ; long-standing experience in biotech start-ups and research environment.

  • Default avatar
    Jean Paul Rohmer
    Director Business Development

    joined Anergis in 2009
    since 2000 Managing Director IDEFI Gestion (Advice and interim management for biotechs and for biotech investors)
    1994-1999 CEO Stallergenes SA, France
    1979-1994 Eli Lilly Pharma France, Head of Pharma Division in the last two years

    Vast experience in Pharma and biotech management, marketing as well as specifcally in allergen immmunotherapy while at Stallergenes

  • Default avatar
    Francois Spertini
    Allergy Medical Expert

    Professor of Medecine
    Chief Immunology/Allergology University Hosptial Lausanne Switzerland
    Founder of Anergis SA in 2001.

Advisors

  • Default avatar
    Carrard et Associés, Lausanne
    Lawyer
    Unconfirmed
    Default avatar
    Ernst & Young
    Accountant
    Unconfirmed

Previous Investors

  • Default avatar
    BioMedInvest, Sunstone Capital, Renaissance PME/Vinci Capital
    Unconfirmed
    Default avatar
    Esperante Ventures, Defi Gestion/Initiative Capital Romandie
    Unconfirmed
    Default avatar
    Private investors
    Unconfirmed